Recursion Pharmaceuticals is maintained at a "Hold" rating, pending further regulatory clarity and late-stage trial ...
Recursion Pharma launches a $200M equity offering and reports a Sanofi milestone but is rated a Hold on limited near-term ...
Leading Healthcare Investors, including Janus Henderson Investors, Invus, Longaeva Partners, ARK Invest, Driehaus Capital ...
Recursion Pharmaceuticals announced a $10 million milestone payment from Sanofi for a new drug candidate targeting ...
The option triggered a $10 million milestone payment to Recursion, bringing total upfront and milestone payments received from Sanofi under the collaboration to $144 million; Recursion is eligible for ...
Recursion Pharmaceuticals, Inc. (“ Recursion ”) (NASDAQ: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives, today ...
Recursion Pharmaceuticals, Inc. announced that Sanofi has optioned the first development candidate from the two companies? multi-program research collaboration. The option triggered a $10 million ...
Elon Musk spent the early hours of October 15 teasing what sounds like Tesla's next major AI unveiling, telling followers ...
As AI companies warn of the dangers of self-improving AI, a new report offers a rare look at how they’re working to make it a ...
Currently, the term "RSI (Recursive Self-Improvement)" is attracting attention in the AI industry.AI rewrites its own code, ...
Ethereum ( ETH -0.45%) co-founder Vitalik Buterin is proposing an intriguing new vision for Ethereum, saying in an essay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results